A CD8+ T-cell Responses Seen Against all Variants

Researchers from the USA have conducted a study suggesting that individuals who have recovered from or been vaccinated against SARS-CoV-2 should maintain effective CD8+ T-cell responses against the major variants that have recently emerged. For the study, the team assessed 45 mutations found in the B.1.1.7, B.1.351, and B.1.1.248 variants that have emerged in the United Kingdom, South Africa, and Brazil, respectively.

The researchers identified amino acid polymorphisms in the B.1.1.7, B.1.351, and B.1.1.248 variants and mapped them to the SARS-CoV-2 genome. They then examined the variants for overlap with the CD8+ epitopes identified in the previous study.

Overall, 132 SARS-CoV-2-specific CD8+ T cell responses occurred, corresponding to 52 unique epitope reactivities targeting several structural and non-structural epitopes across the viral proteome. Of all 45 mapped mutations, insertions, and deletions, only one mutation found in the spike protein of B.1.351 was found to overlap with one of the 52 unique epitopes identified in the previous study. The researchers say the findings suggest that virtually all anti-SARS-CoV-2 CD8+ T-cell responses should recognize the three newly described variants. It is necessary that the vaccines used for widespread campaigns generate strong multivalent T-cell responses in addition to NAb and other humoral responses in order to optimize efficacy against the current SARS-CoV-2 and emerging strains. 

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link:

https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1

#Featured